Selvita is advancing the fight against respiratory diseases
Elevating respiratory research through precise inhalation technology
17 Nov 2023
Selvita has introduced its cutting-edge DSI Buxco® nose-only inhalation and delivery exposure system. This state-of-the-art technology offers researchers an instrument for conducting experiments and administrating treatment with great precision, control, and reproducibility.
Respiratory diseases, including pulmonary fibrosis, asthma, and chronic obstructive pulmonary disease (COPD), represent a significant global health challenge. As the global population continues to grow and age, the burden of these diseases is expected to rise, making innovative clinical research imperative in finding new therapies. In this context, advanced inhalation systems for drug delivery applied in animal models play a crucial role in studying treatment efficacy, disease progression, and disease mechanisms. Additionally, they provide valuable insights, offering a bridge between animal studies and clinical research, facilitating the development of new therapies, and ultimately, improving the lives of those affected by these respiratory conditions.
The delivery system on the DSI Buxco is designed to bring significant benefits to respiratory research. The main key advantage lies in the precise administration of substances in the form of either nebulized liquid or dispersed dry powder that can be used both for inducing the disease and providing therapy. This pinpoint accuracy is essential for a wide range of respiratory models, including those focused on fibrosis, COPD, and asthma. It empowers researchers to explore the complexity of these conditions with great precision.
Efficiency is another important hallmark of the system. It allows researchers to simultaneously expose an entire group of subjects to the desired substance, streamlining the research process and conserving valuable time and resources. Achieving uniform distribution of these elements throughout the lungs is also crucial, ensuring that researchers obtain data they can confidently rely upon. Moreover, the system produces high-quality data that closely resemble clinical read-outs obtained for human respiratory diseases. This emphasis on relevance is of great importance in facilitating effective translational research and potentially uncovering innovative treatments.
Complementing these advantages is the DSI Buxco® FinePointe™ software, which offers real-time monitoring of critical parameters, like accumulated inhaled aerosol, and enhances experimental conditions further optimizing the study. The nose-only inhalation and delivery exposure system, coupled with the advanced monitoring capabilities of DSI Buxco FinePointe software and team of experts, represents a powerful and indispensable tool for researchers in the field of respiratory health.
